


We updated the design of this site on December 18, 2017. [Learn more.](#)

Trial record **1 of 1** for: GFM-DAC-CMML

[Previous Study](#) | [Return to List](#) | [Next Study](#)

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML (GFM-DAC-CMML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal  Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier:
NCT02214407

[Recruitment Status](#)  :

Recruiting

[First Posted](#)  : August 12, 2014

[Last Update Posted](#)  : July 12, 2017

See [Contacts and Locations](#)

Sponsor:

Groupe Francophone des Myelodysplasies

Collaborator:

Janssen-Cilag Ltd.

Information provided by (Responsible Party):

Groupe Francophone des Myelodysplasies

[Study Details](#)

[Tabular View](#)

[No Results Posted](#)

[Disclaimer](#)

Study Description

Go to

Brief Summary:




This is a phase III, two-arm, randomized, stratified, multicenter, open-label study with individual therapeutic benefit aim:

Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML)

The primary objective of the study is to compare between the two arms Event-free Survival (EFS).

Secondary objectives are to compare between both arms:

Overall Survival (OS) Cumulative incidence of AML Overall and Complete Response Rates at 3 and 6 cycles according to IWG 2006 criteria modified for CMML Response duration Toxicity (hematological and non hematological) Prognostic factors

Condition or disease 	Intervention/treatment 	Phase 
MDS	Drug: Decitabine Drug: HYDROXYUREA	Phase 3

Detailed Description:

ARM A: DECITABINE (DAC)

Decitabine (DAC) will be administered at 20 mg/m² intravenously daily for 5 days every 28 days.

Treatment will be delayed at the discretion of the investigator (up to D56) for febrile neutropenia ($\geq 38.5^{\circ}\text{C}$; absolute neutrophil count [ANC], $< 1,000/\mu\text{L}$), clinical and/or microbiologic infection with grade 3 to 4 neutropenia (ANC $< 1,000/\mu\text{L}$), or hemorrhage with grade 4 thrombocytopenia ($< 25,000$ platelets/ μL). If renal or hepatic dysfunction occurs, treatment will be stopped until resolution or withheld if dysfunction persists more than 4 days. Persistent grade 4 thrombocytopenia or neutropenia beyond D49 will mandate bone marrow evaluation.

Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.

Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given.

Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.

ARM B: HYDROXYUREA (HY)

Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.

Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee. This is intended to prevent early dropout, notably in the HY arm.

Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by less than 20% and remains > 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by > 30 X 10⁹/L (if initially below 100 X 10⁹/L). HY will be discontinued in cases of grade 4 thrombocytopenia or neutropenia, and reintroduced at a lower dose after recovery to grade ≤ 3. Persistent grade 4 thrombocytopenia or neutropenia after a 4 week discontinuation will mandate bone marrow evaluation.

Study Design

Go to



[Study Type](#) ⓘ : Interventional (Clinical Trial)

[Estimated Enrollment](#) ⓘ : 168 participants

[Allocation](#): Randomized

[Intervention Model](#): Parallel Assignment

[Masking](#): None (Open Label)

[Primary Purpose](#): Treatment

[Official Title](#): A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)

[Actual Study Start Date](#) ⓘ : October 31, 2014

[Estimated Primary Completion Date](#) ⓘ : December 2017

[Estimated Study Completion Date](#) ⓘ : October 2018

Resource links provided by the National Library of
Medicine



[Drug Information](#) available for: [Hydroxyurea](#)
[Decitabine](#)

[Genetic and Rare Diseases Information Center](#)
resources: [Chronic Myelomonocytic Leukemia](#)

[U.S. FDA Resources](#)

Arms and Interventions

Go to



Arm 	Intervention/treatment
<p>Experimental: ARM A: DECITABINE (DACOGEN)</p> <p>Decitabine (DAC) will be administered at 20 mg/m² intravenously daily for 5 days every 28 days.</p> <p>Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given.</p> <p>Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.</p>	<p>Drug: Decitabine</p> <p>Decitabine (DAC) will be administered at 20 mg/m² intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.</p> <p>Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.</p> <p>Other Name: DACOGEN</p>
<p>Experimental: ARM B: HYDROXYUREA</p> <p>Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.</p> <p>Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by</p>	<p>Drug: HYDROXYUREA</p> <p>Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L.</p> <p>Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.</p>

less than 20% and remains > 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by > 30 X 10⁹/L (if initially below 100 X 10⁹/L). HY will be discontinued in cases of grade 4 thrombocytopenia or neutropenia, and reintroduced at a lower dose after recovery to grade ≤ 3. Persistent grade 4 thrombocytopenia or neutropenia after a 4 week discontinuation will mandate bone marrow evaluation.

Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.

Outcome Measures

Go to



Primary Outcome Measures ⓘ :

1. compare between the two arms Event-free Survival (EFS) [Time Frame: 3 months]

Comparison of Event-free Survival between both arms. Events will include

- Death from any cause
- Disease Progression, defined as one of the following: (i) at any time point: transformation to AML according to WHO criteria ; (ii) after at least 6 cycles of treatment: doubling of bone marrow blasts to > 10%, and worsening of cytopenias lasting for > 4 weeks ; (iii) after at least 3 cycles of treatment: Progression of myeloproliferation (despite maximal HY or DAC dosing; in the absence of concomitant infection) defined as: ≥ 50% increase in spleen size as determined by an imaging technique or doubling in WBC or occurrence of a previously undiagnosed extramedullary localization of the disease.

Secondary Outcome Measures ⓘ :

1. Overall Survival (OS) [Time Frame: 7 month]

Overall survival compared between both Arm of treatment (decitabine and hydroxyurea)

2. Cumulative incidence of AML [Time Frame: 7 month]

Comparison of Cumulative incidence of AML between both arm of treatment (decitabine and hydroxyurea)

3. Overall and Complete Response Rates [Time Frame: 3 month]

Overall and Complete Response Rates at 3 and 6 cycles according to IWG 2006 criteria modified for CMML

4. Response duration [Time Frame: 3 month]

Comparison of response duration after 3 month and 6 month of treatment between both arm of treatment (decitabine and hydroxyurea)

5. Toxicity [Time Frame: 1 month]

hematological and non hematological

6. Prognostic factors [Time Frame: 3 month]

Prognostic factors of Event Free Survival with decitabine and hydroxyurea

Eligibility Criteria

Go to



Information from the National Library of Medicine



Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies](#).

Ages Eligible for Study: 18 Years and older (Adult, Senior)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- Age \geq 18
- CMML diagnosis according to WHO criteria Stable excess in blood monocytes, > 1 G/L
Lack of bcr-abl rearrangement (or Philadelphia chromosome) Bone marrow blast cells $<$

20% Dysplasia of at least one lineage or clonality marker or blood monocytosis during more than 3 months w/o other explanation Blood and marrow smears will be reviewed at each country's level, but morphologist meetings at the 3 country level are planned for better harmonization and review of difficult cases

- WBC \geq 13 G/L Measured on two successive CBC at least two weeks apart, outside of a context of infection.
- Either D1 or D2

D1: At least two of the following criteria, reviewed at each country's level: (modified from Wattel et al. Blood 1996) Marrow blasts \geq 5 % Clonal cytogenetic abnormality (other than t(5;12) (q33; p13) and isolated loss of Y chromosome) Anemia (Hb < 10 g/dL) ANC > 16 G/l (in absence of infection) Thrombocytopenia (platelet count < 100 G/L) Splenomegaly > 5 cm below costal margin (spleen size should also be measured by an imaging technique)

Or:

D2: Extramedullary involvement: Including documented cutaneous, pleural or pericardial effusion.

- No prior treatment (except supportive care, or ESA, or short term (< 6 weeks) HY in patients presenting with high WBC counts)
- Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale.
- Adequate organ function including the following Hepatic : total bilirubin < 1.5 times upper limit of normal (ULN) (except moderate unconjugated hyperbilirubinemia due to intra medullary hemolysis or Gilbert syndrome) , alanine transaminase (ALT) and aspartate transaminase (AST) < 3xULN Renal : serum creatinine < 2 x ULN
- Signed Informed consent
- Negative pregnancy and adequate contraception (including in male patients wishing to father) if relevant.

Exclusion Criteria:

- Myeloproliferative / myelodysplastic syndrome other than CMML
- CMML with t(5 ;12) or PDGFBR rearrangement that may receive imatinib
- Patients eligible for allogeneic bone marrow transplantation with an identified donor
- Pregnant or breastfeeding
- Performance status > 2 on the ECOG Scale.
- Serious concomitant systemic disorder, including active bacterial, fungal or viral infection that in the opinion of the investigator would compromise the safety of the patient and/or his/her ability to complete the study
- Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, or other tumors if not active during the last 3 years)

Information from the National Library of Medicine



To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

*Please refer to this study by its ClinicalTrials.gov identifier (NCT number): **NCT02214407***

Contacts

Contact: Fatiha Chermat +33171207059 fatiha.chermat@sls.aphp.fr

Contact: Pierre Fenaux pierre.fenaux@sls.aphp.fr

Locations

France

- | | |
|---|----------------------------------|
| <p>CHU La Réunion - Site nord
 Saint-Denis, La Réunion, France, 97400
 Contact: Tahar Touahri, MD tahar.touahri@chu-reunion.fr
 Principal Investigator: Tahar Touahri, MD</p> | <p>Not yet recruiting</p> |
| <p>CHU La Réunion-Site Sud
 Saint-Pierre, La Réunion, France, 97410
 Contact: Patricia Zunic, MD patricia.zunic@chu-reunion.fr
 Principal Investigator: Patricia Zunic, MD</p> | <p>Not yet recruiting</p> |
| <p>Chu Amiens
 Amiens, France, 80054
 Contact: Bérengère Gruson, MD 0322455985 gruson.berengere@chu-amiens.fr
 Principal Investigator: Berengere Gruson, MD</p> | <p>Recruiting</p> |
| <p>CHU d'Angers
 Angers, France, 49 000
 Contact: Mathilde Hunault +33 2 41 35 44 75 MaHunault@chu-angers.fr
 Principal Investigator: Mathilde Hunault, Professor</p> | <p>Recruiting</p> |
| <p>CH Victor Dupouy
 Argenteuil, France, 95107</p> | <p>Not yet recruiting</p> |

- Contact: Ahmad Al Jijakli, MD +33134232339 ahmad.aljijakli@ch-argenteuil.fr
Principal Investigator: Ahmad Al Jijakli, MD
- Ch Avignon **Recruiting**
Avignon, France, 84000
Contact: Bohrane Slama, MD 0432753132 bslama@ch-avignon.fr
Principal Investigator: Bohrane Slama, MD
- Centre Hospitalier de La Cote Basque **Not yet recruiting**
Bayonne, France, 64100
Contact: Anne Banos, MD 033559443832 abanos@ch-cotebasque.fr
Principal Investigator: Anne Banos, MD
- Hôpital Avicenne **Recruiting**
Bobigny, France, 93009
Contact: Thorsten Braun, MD (0) 33 1 48 95 70 51 thorsten.braun@avc.aphp.fr
Principal Investigator: Thorsten Braun, MD
- CHU de Brest - Hôpital Morvan **Not yet recruiting**
Brest, France, 29609
Contact: Jean-Richard Eveillard, MD 33 2 98 22 33 33 jean-richard.eveillard@chu-brest.fr
Principal Investigator: Jean-Richard Eveillard, MD
- CHU Côte de Nacre **Recruiting**
Caen, France, 14033
Contact: Stéphane CHEZE, MD 0033231272360 cheze-s@chu-caen.fr
Principal Investigator: Stéphane CHEZE, MD
- CHU Estaing **Not yet recruiting**
Clermont-Ferrand, France, 63058
Contact: Benoit De RENZIS, MD 0334 73 75 00 65 bderenzis@chu-clermontferrand.fr
Principal Investigator: Benoit De RENZIS, MD
- CH de Compiègne **Not yet recruiting**
Compiègne, France, 60321
Contact: Sophie Denetière, MD +33 3 44 23 63 47 s.denetiere@ch-compiegneoyon.fr
Principal Investigator: Sophie Denetière, MD
- Centre Hospitalier Sud-Francilien **Not yet recruiting**
Corbeil-Essonnes, France, 91106
Contact: Célia Salanoubat, MD +33 1 60 90 31 78 celia.salanoubat@ch-sud-francilien.fr

Principal Investigator: Célia Salanoubat, MD

Centre Henri Mondor **Not yet recruiting**
Créteil, France, 94010
Contact: Andrea Toma, MD 0033149812057 andrea.toma@hmn.aphp.fr
Principal Investigator: Andrea Toma, MD

CHU Albert Michallon **Recruiting**
Grenoble, France, 38043
Contact: Stéphane COURBY, MD 033 4 76 76 57 12 SCourby@chu-grenoble.fr
Principal Investigator: Stéphane COURBY, MD
Principal Investigator: Sophie Park, PHD

CH Le Mans **Recruiting**
Le Mans, France, 72000
Contact: Kamel Laribi, MD 0243434361 klaribi@ch-lemans.fr
Principal Investigator: Kamel Laribi, MD

Clinique Victor Hugo **Not yet recruiting**
Le Mans, France, 72000
Contact: Anne Parcelier, MD +33 2 43 47 94 93 a.parcelier@i-l-c.fr
Principal Investigator: Anne Parcelier, MD

Hôpital Saint Vincent de Paul **Not yet recruiting**
Lille, France, 59020
Contact: Christian Rose, MD, PHD +33320874532 rose.christian@ghicl.net
Principal Investigator: Christian Rose, MD, PHD

CHRU de Limoges **Recruiting**
Limoges, France, 87046
Contact: Marie-Pierre Gourin, MD 0033555056651 marie-pierre.gourin@chu-limoges.fr
Principal Investigator: Marie Pierre Gourin, MD

Centre Hospitalier Lyon Sud **Recruiting**
Lyon, France, 69495
Contact: Eric WATTEL, PHD,MD 033 4 72 11 74 01 eric.wattel@chu-lyon.fr
Principal Investigator: Eric WATTEL, PHD,MD

Institut Paoli-Calmette **Recruiting**
Marseille, France, 13009
Contact: Norbert VEY, PHD,MD 033 4 91 22 37 54 veyn@marseille.fnclcc.fr
Principal Investigator: Norbert VEY, PHD,MD

Not yet recruiting

Centre Hospitalier de Meaux
Meaux, France, 77100
Contact: Loïc Fouillard, MD 033164653876 l-fouillard@ch-meaux.fr
Principal Investigator: Loïc Fouillard, MD

Clinique Beausoleil **Not yet recruiting**
Montpellier, France, 34000
Contact: Sophie Auger-Quittet, MD +33467759999 s.auger-quittet@languedoc-mutualite.fr
Principal Investigator: Sophie Auger-Quittet, MD

Hôpital Saint Eloi **Recruiting**
Montpellier, France, 34295
Contact: Robert Navarro, MD +33467338362 r-navarro@chu-montpellier.fr
Principal Investigator: Robert Navarro, MD

Hopital de l'Hotel Dieu **Recruiting**
Nantes, France, 44093
Contact: Pierre Peterlin, MD +33 2 40 08 32 71 pierre.peterlin@chu-nantes.fr
Principal Investigator: Pierre Peterlin, MD

Hopital Archet I **Not yet recruiting**
Nice, France, 06202
Contact: Laurence LEGROS, MD 00 33 4 92 03 58 44 legros.l@chu-nice.fr
Principal Investigator: Laurence LEGROS, MD

CHR d'Orléans **Recruiting**
Orléans, France, 45067
Contact: Ali Arar, MD +33238229546 ali.arar@chr-orleans.fr
Principal Investigator: Ali Arar, MD

Hopital St Louis T4 **Recruiting**
Paris, France, 75475
Contact: Pierre Fenaux, PHD 0171207022 pierre.fenaux@sls.aphp.fr
Principal Investigator: Pierre Fenaux, PHD
Principal Investigator: ITZYKSON Raphael, MD

Centre Hospitalier Joffre **Recruiting**
Perpignan, France, 66046
Contact: Laurence Sanhes, MD 00 33 468616448 laurence.sanhes@ch-perpignan.fr
Principal Investigator: Laurence Sanhes, MD

CHU de Haut-Lévêque **Not yet recruiting**
Pessac, France, 33604
Contact: Sophie Dimicoli-Salazar, MD 033557656511 sophie.dimicoli-salazar@chu-bordeaux.fr
Principal Investigator: Sophie Dimicoli-Salazar, MD

CHU Poitiers **Recruiting**
Poitiers, France, 86021
Contact: Jose Miguel Torregrosa Diaz, MD +33548444444 jose-miguel.torregrosa-diaz@chu-poitiers.fr
Principal Investigator: Jose Miguel Torregrosa Diaz, MD

CH René Dubos **Not yet recruiting**
Pontoise, France, 95000
Contact: Riad Benramdane, MD +33156831442 benramdaner@yahoo.fr
Principal Investigator: Riad Benramdane, MD

CH Annecy Genevois **Not yet recruiting**
Pringy, France, 74374
Contact: Pascale Cony-Makhoul, MD +33 4 50 63 64 31
pconymakhoul@ch-annecygenevois.fr
Principal Investigator: Pascale Cony-Makhoul, MD

CHU de Reims **Not yet recruiting**
Reims, France, 51092
Contact: Chantal HIMBERLIN, MD 003326783644 chimberlin@chu-reims.fr
Principal Investigator: Chantal HIMBERLIN, MD

CHU Pontchaillou **Recruiting**
Rennes, France, 35033
Contact: Stanislas Nimubona, MD 33299289521
stanislas.nimubona@chu-rennes.fr
Principal Investigator: Stanislas Nimubona, MD

Centre Henri Bequerel **Recruiting**
Rouen, France, 76038
Contact: Aspasia STAMATOULLAS, MD 00 33 2 32 08 22 88
aspasia.stamatoullas@chb.unicancer.fr
Principal Investigator: Aspasia STAMATOULLAS, MD

Hôpital Hautepierre **Not yet recruiting**
Strasbourg, France, 67098

Contact: Shanti Natarajan-Ame, MD +33388121670

shanti.ame@chru-strasbourg.fr

Principal Investigator: Shanti Natarajan-Ame, MD

IUCT Oncopole - Département d'hématologie

Not yet recruiting

Toulouse, France, 31059

Contact: Christian RECHER, MD, PHD 05 61 77 20 78

recher.christian@iuct-oncopole.fr

Principal Investigator: Christian RECHER, MD

Iuct Oncopole

Recruiting

Toulouse, France, 31059

Contact: Odile BEYNE-RAUZY, MD, PHD +33(0)5 31 15 62 64

beynerauzy.odile@iuct-oncopole.fr

Principal Investigator: Odile Beyne-Rauzy, PHD

CH Valence

Not yet recruiting

Valence, France, 26953

Contact: Jixing Liu, MD +33475757566 jliu@ch-valence.fr

Principal Investigator: Jixing Liu, MD

CHU Brabois

Not yet recruiting

Vandœuvre-lès-Nancy, France, 54511

Contact: Agnès GUERCI-BRESLER, MD 0033383153281

a.guerci@chu-nancy.fr

Principal Investigator: Agnès GUERCI-BRESLER, MD

Institut gustave Roussy

Not yet recruiting

Villejuif, France, 94805

Contact: Eric Solary, MD +33142114507 eric.solary@igr.fr

Principal Investigator: ERIC SOLARY, MD

Sponsors and Collaborators

Groupe Francophone des Myelodysplasies

Janssen-Cilag Ltd.

Investigators

Principal Investigator: ITZYKSON Raphael, PHD Hopital Saint-Louis, Service hematologie S



More Information

Go to



Responsible Party:

Groupe Francophone des Myelodysplasies

ClinicalTrials.gov Identifier: [NCT02214407](#) [History of Changes](#)

Other Study ID Numbers: **GFM-DAC-CMML**

First Posted: August 12, 2014 [Key Record Dates](#)

Last Update Posted: July 12, 2017

Last Verified: July 2017

Additional relevant MeSH terms:

Benzocaine

Decitabine

Azacitidine

Allopurinol

Hydroxyurea

Anesthetics, Local

Anesthetics

Central Nervous System Depressants

Physiological Effects of Drugs

Sensory System Agents

Peripheral Nervous System Agents

Antimetabolites, Antineoplastic

Antimetabolites

Molecular Mechanisms of Pharmacological
Action

Antineoplastic Agents

Enzyme Inhibitors

Gout Suppressants

Antirheumatic Agents

Free Radical Scavengers

Antioxidants

Protective Agents

Antisickling Agents

Nucleic Acid Synthesis Inhibitors